XTLB X.T.L. Biopharmaceuticals
Pharmaceutical Compositions Comprising 0.25 MG Dose of Synthetic Human Peptides for Treating Systemic Lupus Erythematosus
28 Oct 20
The present invention provides a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B comprising periodic administration to the human subject of one subcutaneous injection of 0.25 mg dose of Edratide every week, so as to treat the human subject.
Murray B. UROWITZ, David ISENBERG, Daniel WALLACE, Monique BEN-AM, Joshua LEVINE, Daphna PARAN
Filed: 15 Jul 20
Patents are sorted by USPTO publication date, most recent first